ZYME NASDAQ
Zymeworks Inc.
1W: +7.2%
1M: +6.4%
3M: +31.1%
YTD: +8.4%
1Y: +62.6%
3Y: +301.2%
5Y: +26.5%
$28.85
+0.48 (+1.69%)
Weekly Expected Move ±6.7%
$24
$26
$28
$30
$32
Credit Risk of going bust: lower than 54% of companies Debt: 11.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.39 (down 99%), Zymeworks Inc. would be worth roughly what it owes.
Total debt $268.6M against a stock market value of $2.04B.
Distance to default 5.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.6M (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' -7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.39 (down 99%), Zymeworks Inc. would be worth roughly what it owes.
Total debt $268.6M against a stock market value of $2.04B.
Distance to default 5.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.6M (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' -7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (82)
Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer
Zymeworks Inc. (NASDAQ:ZYME) Stock Has Average Price Target of $40.64 According to Analysts
Nuvation, Jazz gain new Buys at Citi on oncology prospects
Zymeworks outlines guidance following Theravance acquisition
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME
Zymeworks Completes Acquisition of Theravance Biopharma
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME
3 things to look out for on Friday
Hsbc Holdings PLC Cuts Stock Position in Zymeworks Inc. $ZYME
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $508,000 Position in Zymeworks Inc. $ZYME
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Deutsche Bank AG Buys Shares of 397,190 Zymeworks Inc. $ZYME
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Assenagon Asset Management S.A. Has $32.73 Million Stake in Zymeworks Inc. $ZYME
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?
Theravance Stock Down 3% After Zymeworks Announces Buyout
Theravance downgraded at Jones on Zymeworks acquisition
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal
Zymeworks to Acquire Theravance Biopharma, Inc.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates
Zymeworks (ZYME) Q1 2026 Earnings Transcript
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Near the top of biotech rankings, AbbVie's Q1 beat makes a case for more upside
Zymeworks Inc. (NASDAQ:ZYME) Receives Consensus Rating of “Moderate Buy” from Analysts
JPMorgan Chase & Co. Cuts Stock Position in Zymeworks Inc. $ZYME
Capricorn Fund Managers Ltd Buys Shares of 1,022,840 Zymeworks Inc. $ZYME
Zymeworks appoints Kristin Stafford as CFO
Zymeworks Appoints Kristin Stafford as Chief Financial Officer
Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Rating of “Moderate Buy” by Brokerages
Assenagon Asset Management S.A. Sells 679,400 Shares of Zymeworks Inc. $ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
12 Health Care Stocks Moving In Monday's Pre-Market Session
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Zymeworks Inc. $ZYME Shares Sold by Citigroup Inc.
Q1 Earnings Forecast for Zymeworks Issued By Lifesci Capital
Zymeworks Inc. (NASDAQ:ZYME) Given Average Rating of “Moderate Buy” by Brokerages
Zymeworks (NASDAQ:ZYME) Shares Up 2.8% on Analyst Upgrade
Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028
Zymeworks (ZYME) Q4 2025 Earnings Call Transcript
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Earnings Scheduled For March 2, 2026
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
Earnings Breakdown: Zymeworks Q4
Zymeworks GAAP EPS of -$0.55 misses by $0.21, revenue of $2.52M misses by $18.01M
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Here are the major earnings before the open Monday
Zymeworks Q4 2025 Earnings Preview
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Zymeworks (NYSE:ZYME) and Zomedica (OTC:ZOMDF) Critical Review
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Contrasting Zymeworks (NASDAQ:ZYME) and Generex Biotechnology (OTCMKTS:GNBT)
Zymeworks Announces Participation in Upcoming Investor Conferences
Mark Hollywood Sells 6,120 Shares of Zymeworks (NYSE:ZYME) Stock
Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Zymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of “Buy” from Analysts
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Zymeworks (NYSE:ZYME) Insider Paul Andrew Moore Sells 20,110 Shares of Stock
Zymeworks (NYSE:ZYME) EVP Jeffrey Smith Sells 10,538 Shares
Zymeworks Inc. $ZYME Shares Purchased by Assenagon Asset Management S.A.
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Buy” from Brokerages
Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Zymeworks Announces Participation in Upcoming Conferences
Critical Review: Acerus Pharmaceuticals (OTCMKTS:ASPCF) vs. Zymeworks (NASDAQ:ZYME)
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA
Zymeworks: A Lot Of Moving Parts